COMMUNIQUÉS West-GlobeNewswire

-
Aixplorer Mach 30 SuperSonic Imagine Pushes the Boundaries of Ultrasound Imaging
25/04/2018 - 19:00 -
Stealth Mark Collaborates with Oak Ridge National Labs on Next Generation Authentication
25/04/2018 - 18:17 -
Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (mBC) at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
25/04/2018 - 18:15 -
Genmab Announces Data to be Presented at 2018 ASCO Annual Meeting
25/04/2018 - 17:59 -
BioSyent to Present at Upcoming Investor Conferences
25/04/2018 - 17:45 -
CV Sciences, Inc. Fully Retires Convertible Debt
25/04/2018 - 17:08 -
Tauriga Sciences Inc. to Present at European Institutional Investor Conference on June 21, 2018 in Berlin, Germany; Venue is the Representative Office of Baden-Wurttemberg in Berlin
25/04/2018 - 17:01 -
Tauriga Sciences Inc. Board of Directors Approves 1 for 75 Reverse Split, Reducing Its Outstanding Common Stock to Approximately 52,300,000 Shares With a Proportional Reduction of Its Authorized Common Stock to 100,000,000 Shares
25/04/2018 - 16:10 -
Scythian Biosciences Corp. Announces the Appointment of European Cannabis Leader Rob Reid of Prohibition Partners as CEO
25/04/2018 - 15:06 -
Progyny and RESOLVE to Ring the Nasdaq Stock Market Closing Bell in Recognition of National Infertility Awareness Week®
25/04/2018 - 15:00 -
Teladoc Announces U.S. Launch of Behavioral Health Navigator
25/04/2018 - 14:35 -
Cesca Therapeutics Inc. to Exhibit at Several Upcoming Cell Therapy Conferences
25/04/2018 - 14:30 -
Sientra to Showcase OPUS™ Breast Products and miraDry fresh™ Procedure at American Society of Aesthetic Plastic Surgeons Meeting
25/04/2018 - 14:30 -
Profound Medical to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference
25/04/2018 - 14:30 -
Ascendis Pharma A/S Announces Upcoming Investor Presentations
25/04/2018 - 14:30 -
Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals (Up to 32.5 days) and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine
25/04/2018 - 14:30 -
Targovax ASA: Issuance of restricted stock units (RSUs) to the board members
25/04/2018 - 14:18 -
GTX Corp Sponsor and Presenter at the Safe America World Safe Symposium
25/04/2018 - 14:15 -
Extendicare Announces Closing of Underwriters' $16.5 Million Over-Allotment Option of 5.00% Convertible Debentures
25/04/2018 - 14:11
Pages